NEW YORK, Feb. 17, 2021 Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system . | February 21, 2021
Pune, Maharashtra, India, February 15 2021 (Wiredrelease) Allied Analytics –:Depression affects a person’s thoughts, behavior, feelings and sense of well-being and is caused due to biological, genetics, environment, and psychological factors. The symptoms usually include low mood and aversion to physical activity. D.
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
February 08, 2021 07:30 ET | Source: Dyne Therapeutics, Inc. Dyne Therapeutics, Inc. Waltham, Massachusetts, UNITED STATES
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease
WALTHAM, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Ashish Dugar, Ph.D., MBA, as senior vice president, global head of medical affairs. Dr. Dugar brings over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Major players in the Alzheimer s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.
The global Alzheimer s disease treatment market is expected to decline from $3.46 billion in 2019 to $3.42 billion in 2020 at a compound annual growth rate (CAGR) of -1.26%.
The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $4.96 billion in 2023 at a CAGR of 13.21%.
Global Alzheimer s Disease Treatment Market Report 2020: 2015-2019, 2023F, 2025F, 2030F
February 03, 2021 05:43 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
ResearchAndMarkets.com s offering.
Major players in the Alzheimer s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.
The global Alzheimer s disease treatment market is expected to decline from $3.46 billion in 2019 to $3.42 billion in 2020 at a compound annual growth rate (CAGR) of -1.26%.
The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to